A First Look At Lyell Immunopharma [Seeking Alpha]
Lyell Immunopharma, Inc. (LYEL)
Company Research
Source: Seeking Alpha
Ronde-cel's registrational trial targets impressive potential results, with pivotal data expected mid-2027 and BLA submission in 2H27. LYL273, recently in-licensed for metastatic colorectal cancer, demonstrated a 67% ORR and 8-month mPFS at dose level 2; pivotal trial initiation is planned for 1H27. Despite a $300 million premium to cash and a history of clinical failures, LYEL is a high-risk, high-reward play best suited for aggressive, risk-tolerant investors. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » wildpixel/iStock via Getty Images Shares of cell therapy concern Lyell Immunopharma, Inc. ( LYEL have retreated by around half since spiking to $45 in December 2025 after being upgraded by HC Wainwright and Seeking Alpha's PQP. Those moves were somewhat triggered by More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trade
Show less
Read more
Impact Snapshot
Event Time:
LYEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYEL alerts
High impacting Lyell Immunopharma, Inc. news events
Weekly update
A roundup of the hottest topics
LYEL
News
- Lyell Immunopharma (LYEL) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LYEL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell"MarketBeat
- Lyell Immunopharma, Inc. (LYEL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Lyell Immunopharma (LYEL) is now covered by Needham & Company LLC. They set a "buy" rating and a $44.00 price target on the stock.MarketBeat
- Lyell Immunopharma (LYEL) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
LYEL
Sec Filings
- 4/24/26 - Form ARS
- 4/24/26 - Form DEFA14A
- 4/24/26 - Form DEF
- LYEL's page on the SEC website